Literature DB >> 15111255

Assessment of neurotoxicity following repeated cremophor/ethanol injections in rats.

N Authier1, J P Gillet, J Fialip, A Eschalier, F Coudore.   

Abstract

As the mixture cremophor/ethanol is known to have side-effects affecting the peripheral nervous system, we have assessed its behavioural and morphological neurotoxicity after repeated intraperitoneal injections in male Sprague Dawley rats. Clinical status of the animals was good throughout the experiment and no motor deficits were observed. Nevertheless, sensory testing demonstrated an hyperalgesia and an allodynia to mechanical stimuli, associated to peripheral axon degeneration.

Entities:  

Year:  2001        PMID： 15111255     DOI： 10.1007/bf03033269

Source DB:  PubMed          Journal:  Neurotox Res        ISSN： 1029-8428            Impact factor:   3.911


  10 in total

1.  A method for measurement of analgesic activity on inflamed tissue.

Authors:  L O RANDALL; J J SELITTO
Journal:  Arch Int Pharmacodyn Ther       Date:  1957-09-01

2.  Emulsifier for intravenous cyclosporin inhibits neurite outgrowth, causes deficits in rapid axonal transport and leads to structural abnormalities in differentiating N1E.115 neuroblastoma.

Authors:  D J Brat; A J Windebank; S Brimijoin
Journal:  J Pharmacol Exp Ther       Date:  1992-05       Impact factor: 4.030

3.  A method for the routine assessment of fore- and hindlimb grip strength of rats and mice.

Authors:  O A Meyer; H A Tilson; W C Byrd; M T Riley
Journal:  Neurobehav Toxicol       Date:  1979

4.  A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia.

Authors:  K Hargreaves; R Dubner; F Brown; C Flores; J Joris
Journal:  Pain       Date:  1988-01       Impact factor: 6.961

5.  Ethical guidelines for investigations of experimental pain in conscious animals.

Authors:  Manfred Zimmermann
Journal:  Pain       Date:  1983-06       Impact factor: 6.961

6.  Ethylene oxide neurotoxicity: a cluster of 12 nurses with peripheral and central nervous system toxicity.

Authors:  A Brashear; F W Unverzagt; M O Farber; J M Bonnin; J G Garcia; E Grober
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

7.  Differential activity of Cremophor EL and paclitaxel in patients' tumor cells and human carcinoma cell lines in vitro.

Authors:  K Csóka; S Dhar; H Fridborg; R Larsson; P Nygren
Journal:  Cancer       Date:  1997-03-15       Impact factor: 6.860

8.  Quantitative assessment of tactile allodynia in the rat paw.

Authors:  S R Chaplan; F W Bach; J W Pogrel; J M Chung; T L Yaksh
Journal:  J Neurosci Methods       Date:  1994-07       Impact factor: 2.390

9.  Potential neurotoxicity of the solvent vehicle for cyclosporine.

Authors:  A J Windebank; M D Blexrud; P C de Groen
Journal:  J Pharmacol Exp Ther       Date:  1994-02       Impact factor: 4.030

10.  Noxious thermal input from the rat tail: modulation by descending inhibitory influences.

Authors:  R Necker; R F Hellon
Journal:  Pain       Date:  1978-02       Impact factor: 6.961
  10 in total
  12 in total

1.  Nanoparticle albumin-bound-paclitaxel: a limited improvement under the current therapeutic paradigm of pancreatic cancer.

Authors:  Robert M Hoffman; Michael Bouvet
Journal:  Expert Opin Pharmacother       Date:  2015-05       Impact factor: 3.889

Review 2.  The potential feasibility of nab-paclitaxel as the first-line chemotherapy for ovarian cancer: clinical development and future perspectives.

Authors:  Xue Yang; Chun Fu
Journal:  Arch Gynecol Obstet       Date:  2022-02-14       Impact factor: 2.493

3.  Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors.

Authors:  Thomas E Stinchcombe; Mark A Socinski; Christine M Walko; Bert H O'Neil; Frances A Collichio; Anastasia Ivanova; Hua Mu; Michael J Hawkins; Richard M Goldberg; Celeste Lindley; E Claire Dees
Journal:  Cancer Chemother Pharmacol       Date:  2007-02-07       Impact factor: 3.333

4.  Weekly nab-Paclitaxel in Metastatic Breast Cancer - Summary and Results of an Expert Panel Discussion.

Authors:  Christian Jackisch; Hans-Joachim Lück; Michael Untch; Joachim Bischoff; Volkmar Müller; Marcus Schmidt; Marc Thill; Marion Kiechle
Journal:  Breast Care (Basel)       Date:  2012-04-16       Impact factor: 2.860

5.  Increased elimination of paclitaxel by magnesium isoglycyrrhizinate in epithelial ovarian cancer patients treated with paclitaxel plus cisplatin: a pilot clinical study.

Authors:  Kai Jie Chen; Wan Yi Chen; Xia Chen; Yi Ming Jia; Gui Qin Peng; Li Chen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-05-17       Impact factor: 2.441

6.  Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations.

Authors:  Daniel Y Zhang; Crismita Dmello; Li Chen; Victor A Arrieta; Edgar Gonzalez-Buendia; J Robert Kane; Lisa P Magnusson; Aneta Baran; C David James; Craig Horbinski; Alexandre Carpentier; Carole Desseaux; Michael Canney; Miguel Muzzio; Roger Stupp; Adam M Sonabend
Journal:  Clin Cancer Res       Date:  2019-12-12       Impact factor: 12.531

7.  Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval.

Authors:  Yutaka Yamamoto; Ichiro Kawano; Hirotaka Iwase
Journal:  Onco Targets Ther       Date:  2011-07-18       Impact factor: 4.147

8.  Peritoneal tumor carcinomatosis: pharmacological targeting with hyaluronan-based bioconjugates overcomes therapeutic indications of current drugs.

Authors:  Isabella Monia Montagner; Anna Merlo; Gaia Zuccolotto; Davide Renier; Monica Campisi; Gianfranco Pasut; Paola Zanovello; Antonio Rosato
Journal:  PLoS One       Date:  2014-11-10       Impact factor: 3.240

9.  Weekly nanoparticle albumin-bound paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma.

Authors:  Hai-Ying Wang; Zhi-Hua Yao; Hong Tang; Yan Zhao; Xiao-San Zhang; Shu-Na Yao; Shu-Jun Yang; Yan-Yan Liu
Journal:  Onco Targets Ther       Date:  2016-09-23       Impact factor: 4.147

10.  Adverse event profiles of solvent-based and nanoparticle albumin-bound paclitaxel formulations using the Food and Drug Administration Adverse Event Reporting System.

Authors:  Misa Naganuma; Kohei Tahara; Shiori Hasegawa; Akiho Fukuda; Sayaka Sasaoka; Haruna Hatahira; Yumi Motooka; Satoshi Nakao; Ririka Mukai; Kouseki Hirade; Tomoaki Yoshimura; Takeshi Kato; Hirofumi Takeuchi; Mitsuhiro Nakamura
Journal:  SAGE Open Med       Date:  2019-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.